Overview
Title
To amend the Federal Food, Drug, and Cosmetic Act to modernize the methods of authenticating controlled substances in the pharmaceutical distribution supply chain, and for other purposes.
ELI5 AI
H. R. 1060 is like a special rule that wants to make sure medicines are real and not fake. It says that in the future, each pill must have a tiny secret code that machines can read to check if the medicine is true or false.
Summary AI
H. R. 1060 proposes to amend the Federal Food, Drug, and Cosmetic Act to update how controlled substances are verified and authenticated during their distribution. The bill requires that each dose of controlled substances manufactured from five years after the bill's enactment must include a "physical chemical identifier," which is a unique marker that can be read by machines to confirm the medicine's authenticity. Additionally, it redefines certain terms related to product identification and verification to incorporate this new technology.
Published
Keywords AI
Sources
Bill Statistics
Size
Language
Complexity
AnalysisAI
General Summary of the Bill
The proposed legislation, titled the "Modern Authentication of Pharmaceuticals Act of 2025," seeks to amend the Federal Food, Drug, and Cosmetic Act. The bill, introduced by Representative Davis of North Carolina alongside Representatives Rutherford and Bacon, aims to modernize the authentication processes of controlled substances within the pharmaceutical distribution supply chain. It emphasizes the use of a "physical chemical identifier" (PCI) to be included in or on each dose of a controlled substance, specifically those in solid oral form. This requirement is set to be implemented five years following the enactment of this legislation.
Summary of Significant Issues
One of the primary concerns with the bill is the requirement that each dose of a controlled substance must contain a PCI. This could result in substantial compliance costs for pharmaceutical manufacturers, especially affecting smaller companies. Moreover, the term "physical chemical identifier" remains vaguely defined within the bill, potentially leading to differing interpretations and enforcement challenges.
Another significant issue is the bill's reference to a "widely recognized international standards development organization" without specifying which organizations qualify. This vagueness could result in inconsistent adherence to standards internationally, complicating trade and regulatory consistency.
The act's linkage to the "Modern Authentication of Pharmaceuticals Act of 2025"—a future act not yet enacted—introduces uncertainty into the legislation. This dependence could create planning challenges for stakeholders, as they cannot anticipate when or if certain requirements will be implemented.
Lastly, the bill's inclusion of both standardized numerical identifiers and PCIs might introduce unnecessary complexity into the pharmaceutical supply chain, adding operational burdens for companies striving to comply.
Impact on the Public Broadly
The goals of the bill, centered around improving the authentication of pharmaceuticals, are intended to enhance drug safety and security in the distribution chain. By potentially reducing counterfeit drugs and ensuring authenticity, the public stands to benefit from safer pharmaceuticals. However, should the compliance costs lead to increased drug prices, consumers might experience a financial impact due to the higher costs of medications.
Impact on Specific Stakeholders
Small pharmaceutical companies are likely to face the greatest challenges under this bill. The financial and operational demands of complying with the PCI requirement could strain their resources, possibly driving some out of the market or discouraging entry into the market. This could diminish competition in the pharmaceutical industry, potentially leading to higher drug prices.
Regulators might face difficulties enforcing the unclear standards and definitions within the bill, which could hinder effective implementation. Conversely, technology companies specializing in authentication solutions may experience increased demand for their services, presenting them with new business opportunities.
In conclusion, while the bill aims to address significant issues concerning pharmaceutical authenticity and safety, various aspects require careful reevaluation to ensure the legislation's practicality, fairness, and economic viability for all stakeholders involved.
Issues
The requirement for every dose of controlled substances in solid oral form to include a 'physical chemical identifier' (PCI) as per Section 2(a) introduces potential significant compliance costs for manufacturers. This may affect smaller pharmaceutical companies disproportionally, leading to higher drug prices or decreased market competition.
The definition of 'physical chemical identifier' in Section 2(b)(1)(B) is vague and could lead to ambiguity in interpretation and enforcement. The lack of clarity on what constitutes a PCI might create legal challenges or inconsistencies across the industry, impacting both compliance efforts and regulatory enforcement.
The reference to a 'widely recognized international standards development organization' in Section 2(b)(1)(A) is imprecise, potentially leading to variable adherence to standards and confusion over what organizations are considered 'widely recognized', affecting international trade and regulatory processes.
The bill references the 'Modern Authentication of Pharmaceuticals Act of 2025', a future act that has not been enacted yet, creating uncertainty around the timeline and implementation of this legislation (noted in both Section 2(a) and the Short Title). This dependency on future legislative action that is not guaranteed could lead to planning difficulties for stakeholders.
Section 2's introduction of both standardized numerical identifiers and physical chemical identifiers could lead to unnecessary complexity in the pharmaceutical supply chain. This may complicate compliance efforts and increase operational burdens for pharmaceutical companies.
The requirement for PCI implementation within five years as noted in Section 2(a) may not provide enough transition time for all industry players, particularly smaller companies, which could face greater financial and operational strain to meet new compliance obligations.
Sections
Sections are presented as they are annotated in the original legislative text. Any missing headers, numbers, or non-consecutive order is due to the original text.
1. Short title Read Opens in new tab
Summary AI
The section states that this law can be called the “Modern Authentication of Pharmaceuticals Act of 2025.”
2. Modernizing the authentication of controlled substances in the pharmaceutical distribution supply chain Read Opens in new tab
Summary AI
The bill section proposes amendments to the Federal Food, Drug, and Cosmetic Act to require the inclusion of a physical chemical identifier on controlled substances in solid oral dosage form starting five years after the enactment of the Modern Authentication of Pharmaceuticals Act of 2025. It also updates definitions to include this identifier as an option for the verification of products, which can be read by machines to confirm the authenticity of pharmaceuticals.